Welcome to our dedicated page for Beyondspring SEC filings (Ticker: BYSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BeyondSpring Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on cancer therapies, including Plinabulin development, financial results and capital structure. Its Form 10-K and Form 8-K disclosures cover audited consolidated financial statements, quarterly and annual operating results, clinical-program updates, and risk and business information tied to oncology development.
Current reports also record material agreements, registered offerings of ordinary shares, SEED Therapeutics financing and ownership disclosures, and shareholder-vote results from annual meetings. These filings describe governance actions, securities issuances, registration-statement use and other material events affecting BeyondSpring’s public-company reporting.
BeyondSpring Inc. (BYSI) furnished a current report to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference.
The company states the information in this report, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act.
BeyondSpring (BYSI): Decheng Capital–affiliated reporting persons, identified as a director, reported open-market sales of ordinary shares. On 10/16/2025, Fund III sold 85,798 shares at a weighted average price of $1.72 (prices ranged from $1.62 to $1.795). On 10/17/2025, Fund III sold 45,513 shares at a weighted average price of $1.76 (prices ranged from $1.73 to $1.80).
Following these transactions, Fund III reported 1,518,893 shares beneficially owned indirectly. Separate indirect holdings reported were 1,617,409 shares by Fund II and 891,734 shares by the Global Healthcare Fund. The sales were executed across multiple prices, with full trade breakdowns available upon request as noted in the footnotes.
BeyondSpring (BYSI) reported insider transactions by Decheng Capital–affiliated funds. Decheng Capital China Life Sciences USD Fund III, L.P. reported sales of 107,361 ordinary shares on 10/13/2025 at a weighted average price of $1.70 (range $1.69–$1.75), 28,495 shares on 10/14/2025 at $1.65 (range $1.62–$1.70), and 17,960 shares on 10/15/2025 at $1.65 (range $1.60–$1.685). Following these trades, Fund III reported 1,650,204 shares indirectly held. Other reported indirect holdings were 1,617,409 shares by Fund II and 891,734 shares by the Global Healthcare Fund.
Decheng Capital affiliates and Dr. Xiangmin Cui reported insider sales of BeyondSpring Inc. (BYSI) ordinary shares across three trading dates. Fund III sold 7,507 shares on 10/08/2025 at a weighted average price of $1.77, 3,979 shares on 10/09/2025 at a weighted average price of $1.81, and 2,390 shares on 10/10/2025 at a weighted average price of $1.77, totaling 13,876 shares sold. After these transactions, Fund III reports beneficial ownership of 1,804,020 shares. Related Decheng entities report additional indirect holdings of 1,617,409 and 891,734 shares respectively, held by Fund II and the Global Healthcare master fund. The filing discloses that reported prices are weighted averages across specified price ranges and that general partners and Dr. Cui may be deemed to beneficially own the funds' holdings while disclaiming direct ownership beyond pecuniary interest.
BeyondSpring Inc. (BYSI): Decheng Capital-affiliated reporting persons disclosed open-market sales of ordinary shares. On 10/03, 600 shares were sold at $1.76 (weighted average range $1.73–$1.79); on 10/06, 17,500 shares at $1.78 (range $1.73–$1.7879); and on 10/07, 2,100 shares at $1.79 (range $1.74–$1.80). The filing is made by more than one reporting person, noted as Director and 10% Owner.
Following these transactions, indirect beneficial holdings were reported as 1,817,896 shares by Decheng Capital China Life Sciences USD Fund III, L.P., 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P., and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP.
Decheng Capital reporting persons, including funds managed by Dr. Xiangmin Cui, disclosed insider sales of 7,665 BeyondSpring Inc. (BYSI) ordinary shares across three days. The filings show 4,464 shares sold on 09/30/2025 at a weighted average price of about $1.81, 2,601 shares sold on 10/01/2025 at about $1.80, and 600 shares sold on 10/02/2025 at about $1.73. After the reported transactions, Decheng Capital China Life Sciences USD Fund III, L.P. is shown as beneficially owning approximately 1,838,096–1,841,297 shares (per line entries), while affiliated funds report holdings of 1,617,409 and 891,734 shares respectively. The footnotes state the prices are weighted averages within disclosed ranges and confirm the reporting chain through GP entities managed by Dr. Cui.
Decheng Capital entities disclosed multiple small sales of BeyondSpring Inc. (BYSI) ordinary shares in late September 2025. Fund III sold 1,800 shares on 09/25/2025 through 09/29/2025 in three reported transactions (700 at a weighted average $1.66, 600 at $1.68, 500 at $1.75), reducing Fund III's reported holdings to 1,845,761 shares after the last sale. Related Decheng entities report additional indirect holdings of 1,617,409 shares (Fund II) and 891,734 shares (Global Healthcare Master).
The filings identify Decheng Capital Management III (GP III) and Dr. Xiangmin (Cui) as manager/related parties and state that GP and Dr. Cui may be deemed beneficial owners of the funds' holdings but disclaim direct ownership except for pecuniary interest. The transactions are reported as sales with weighted average price ranges disclosed in footnotes.
Decheng Capital-related funds and manager Dr. Xiangmin Cui reported insider sales of BeyondSpring Inc. (BYSI) ordinary shares over three consecutive days in September 2025. The filings show Fund III sold 5,410 shares on 09/22/2025 at a weighted average price of $1.83, 4,106 shares on 09/23/2025 at $1.72, and 2,256 shares on 09/24/2025 at $1.68, for a total of 11,772 shares sold across the three transactions. After these sales, Fund III beneficially owned 1,847,561 shares. The Form 4 also discloses indirect holdings by affiliated vehicles: Fund II holds 1,617,409 shares and Decheng Capital Global Healthcare Fund (Master) holds 891,734 shares. The filings state the reported prices are weighted averages for multiple transactions within specified ranges and identify Decheng Capital management entities and Dr. Cui as the reporting persons.
BeyondSpring Inc. reports that its majority-owned indirect subsidiary SEED Therapeutics Inc. has completed a second closing of its Series A-3 financing. On September 22, 2025, SEED entered into share purchase agreements with third-party investors to sell an aggregate of 1,411,761 Series A-3 Preferred Shares for an aggregate cash purchase price of $6 million, at $4.25 per share.
This follows SEED’s August 2024 sale of 5,647,059 Series A-3 Preferred Shares for $24 million at the same price per share. After the second close, BeyondSpring and its subsidiary SEED Technology Limited are expected to own approximately 38.03% of SEED’s outstanding equity on an as-converted basis, excluding any employee equity plans. BeyondSpring expects that SEED will continue to be consolidated into its financial statements because BeyondSpring believes it remains in substantive control of SEED.
BeyondSpring Inc. reports that its majority-owned indirect subsidiary SEED Therapeutics Inc. has completed a second closing of its Series A-3 financing. On September 22, 2025, SEED entered into share purchase agreements with third-party investors to sell an aggregate of 1,411,761 Series A-3 Preferred Shares for an aggregate cash purchase price of $6 million, at $4.25 per share.
This follows SEED’s August 2024 sale of 5,647,059 Series A-3 Preferred Shares for $24 million at the same price per share. After the second close, BeyondSpring and its subsidiary SEED Technology Limited are expected to own approximately 38.03% of SEED’s outstanding equity on an as-converted basis, excluding any employee equity plans. BeyondSpring expects that SEED will continue to be consolidated into its financial statements because BeyondSpring believes it remains in substantive control of SEED.
Decheng Capital entities reported insider dispositions of BeyondSpring Inc. (BYSI) ordinary shares across three days in September 2025. Decheng Capital China Life Sciences USD Fund III sold 2,304 shares on 09/17/2025 at a weighted average price of $1.83, 5,307 shares on 09/18/2025 at $1.74, and 3,656 shares on 09/19/2025 at $1.79, totaling 11,267 shares sold and leaving Fund III with 1,859,333 shares. The filing also shows indirect holdings of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Footnotes explain weighted average pricing ranges and that GP entities and Dr. Xiangmin Cui may be deemed beneficial owners but disclaim direct ownership except for pecuniary interest.
Decheng Capital entities reported insider dispositions of BeyondSpring Inc. (BYSI) ordinary shares across three days in September 2025. Decheng Capital China Life Sciences USD Fund III sold 2,304 shares on 09/17/2025 at a weighted average price of $1.83, 5,307 shares on 09/18/2025 at $1.74, and 3,656 shares on 09/19/2025 at $1.79, totaling 11,267 shares sold and leaving Fund III with 1,859,333 shares. The filing also shows indirect holdings of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Footnotes explain weighted average pricing ranges and that GP entities and Dr. Xiangmin Cui may be deemed beneficial owners but disclaim direct ownership except for pecuniary interest.